How I Manage Hypertension and Proteinuria Associated with VEGF Inhibitor.
作者信息
Rashidi Arash, Wanchoo Rimda, Izzedine Hassan
机构信息
Division of Nephrology & Hypertension, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Division of Kidney Diseases and Hypertension, The Glomerular Center at Northwell, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York.
出版信息
Clin J Am Soc Nephrol. 2023 Jan 1;18(1):121-123. doi: 10.2215/CJN.05610522. Epub 2022 Aug 17.
Abstract
摘要
相似文献
1
How I Manage Hypertension and Proteinuria Associated with VEGF Inhibitor.
Clin J Am Soc Nephrol. 2023 Jan 1;18(1):121-123. doi: 10.2215/CJN.05610522. Epub 2022 Aug 17.
2
Trends in renal function following vascular endothelial growth factor inhibitor administration in patients with cancer and diabetes mellitus.
Cancer Chemother Pharmacol. 2025 Jul 2;95(1):69. doi: 10.1007/s00280-025-04793-6.
3
Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.
PLoS One. 2014 Jul 2;9(7):e101145. doi: 10.1371/journal.pone.0101145. eCollection 2014.
4
Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management.
Folia Biol (Praha). 2013;59(1):15-25.
5
Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Anticancer Drugs. 2009 Jan;20(1):81-2. doi: 10.1097/CAD.0b013e3283161012.
6
[Renovascular effects of antiangiogenic drugs].
Bull Cancer. 2016 Jul-Aug;103(7-8):662-6. doi: 10.1016/j.bulcan.2016.05.005. Epub 2016 Jun 16.
7
Proteinuria and VEGF-targeted therapies:
an underestimated toxicity?
J Nephrol. 2013 Sep-Oct;26(5):807-10. doi: 10.5301/jn.5000307. Epub 2013 Aug 7.
8
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.
Cancer Treat Rev. 2024 Jan;122:102652. doi: 10.1016/j.ctrv.2023.102652. Epub 2023 Nov 4.
9
Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Hum Pathol. 2014 Sep;45(9):1918-27. doi: 10.1016/j.humpath.2014.05.015. Epub 2014 Jun 12.
10
Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.
Kidney Int. 2019 Sep;96(3):572-580. doi: 10.1016/j.kint.2019.02.042. Epub 2019 Apr 9.
引用本文的文献
1
Ten tips for an onco-nephrology clinic.
Clin Kidney J. 2025 May 29;18(6):sfaf174. doi: 10.1093/ckj/sfaf174. eCollection 2025 Jun.
2
Off-label use of anlotinib in malignancies' treatment: efficacy and management of adverse reactions.
Pharmacol Rep. 2025 Apr;77(2):392-408. doi: 10.1007/s43440-025-00700-1. Epub 2025 Feb 3.
3
Acute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies.
Kidney360. 2024 Nov 1;5(11):1750-1762. doi: 10.34067/KID.0000000566. Epub 2024 Aug 26.
4
Effect of blood pressure control on the risk of proteinuria during bevacizumab treatment in patients with colorectal cancer: a single-center retrospective cohort study.
J Pharm Health Care Sci. 2024 Aug 23;10(1):51. doi: 10.1186/s40780-024-00372-8.
5
Management of hypertension in patients with cancer: challenges and considerations.
Clin Kidney J. 2023 Aug 12;16(12):2336-2348. doi: 10.1093/ckj/sfad195. eCollection 2023 Dec.
6
Onconephrology 2022: An Update.
Kidney360. 2023 Feb 1;4(2):258-271. doi: 10.34067/KID.0001582022. Epub 2022 Dec 9.
本文引用的文献
1
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.
PLoS One. 2015 Jan 20;10(1):e0116527. doi: 10.1371/journal.pone.0116527. eCollection 2015.
2
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.
Cancer. 2015 Jan 15;121(2):311-9. doi: 10.1002/cncr.28972. Epub 2014 Sep 18.
3
Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
Kidney Int. 2014 Feb;85(2):457-70. doi: 10.1038/ki.2013.344. Epub 2013 Sep 25.
4
Proteinuria and VEGF-targeted therapies:
an underestimated toxicity?
J Nephrol. 2013 Sep-Oct;26(5):807-10. doi: 10.5301/jn.5000307. Epub 2013 Aug 7.
5
Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer.
Clin J Oncol Nurs. 2013 Aug 1;17(4):425-33. doi: 10.1188/13.CJON.425-433.
6
β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma.
Br J Cancer. 2013 Jun 25;108(12):2485-94. doi: 10.1038/bjc.2013.205. Epub 2013 May 21.
7
Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.
Oncologist. 2013;18(3):273-80. doi: 10.1634/theoncologist.2012-0339. Epub 2013 Mar 13.
8
Bevacizumab increases risk for severe proteinuria in cancer patients.
J Am Soc Nephrol. 2010 Aug;21(8):1381-9. doi: 10.1681/ASN.2010020167. Epub 2010 Jun 10.
9
Hypertension as a surrogate marker for the activity of anti-VEGF agents.
Ann Oncol. 2009 May;20(5):967-70. doi: 10.1093/annonc/mdp206.
10
Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
Am J Kidney Dis. 2007 Aug;50(2):203-18. doi: 10.1053/j.ajkd.2007.04.025.
Zotero 插件